Key result
Complete macroscopic surgical resection remains the mainstay treatment and only potential cure for retroperitoneal sarcoma.
Surgical resection remains the mainstay of treatment for retroperitoneal sarcomas, with a need for global multi-institutional collaboration to optimize management.
Affirms surgical resection as mainstay for retroperitoneal sarcoma; leaves open need for global collaboration to optimize outcomes.
Retroperitoneal sarcomas (RPS) are rare cancers that often reach massive size before detection. The mainstay of treatment for RPS is surgical resection, and complete resection is the only chance for potential cure. The management of RPS can be challenging and in individual cases, radiation and systemic therapy may be beneficial in both primary and recurrent disease. Further research through multi-institutional collaboration, ideally on a global level, is needed to better understand RPS and optimize management of this disease.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2018) conducted a review in Retroperitoneal sarcoma. Surgical resection was evaluated. Surgical resection with complete macroscopic removal remains the mainstay of treatment and the only potential chance for cure for retroperitoneal sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: